Concarlo Holdings Combats Resistant Metastatic Breast Cancer with Dual Receptor Therapeutic

Breast cancer is the most common cancer diagnosed among women. Over a lifetime, approximately 1 in 8 women develop breast cancer. When treated early, survival rates at five years are 100%. However, for more advanced states, survival rates decline significantly. Over 3 million women live with a current or previous diagnosis of breast cancer. Any …

Concarlo Holdings Combats Resistant Metastatic Breast Cancer with Dual Receptor Therapeutic Read More »